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AUTOLOGOUS MESENCHYMAL STEM CELLS IN NONUNION FRACTURES 
JOHN DREIER 
ABSTRACT 
 The current gold standard of therapy for treatment of tibial fracture nonunion is 
iliac crest bone graft. However, this intervention is associated with significant morbidity 
to the donor site. Research into alternative interventions highlights the role of 
mesenchymal stem cells (MSCs). MSCs are capable of differentiating into mature, 
organized osseous tissue as well as recruiting local vascular cells. However, there are few 
prospective studies demonstrating the therapeutic potential of MSCs in fracture 
nonunion. The proposed study is a multicenter single-blinded controlled study of MSC 
application compared to iliac crest bone graft in the setting of fracture nonunion of the 
tibia. The study subjects will be evaluated at each return to care with mRUST 
radiographic scoring as well as Short-Form 12 evaluation of general health. These results 
will be correlated with MSC concentrations as assessed by FACS analysis. The data from 
this study will help to characterize MSCs as a possible therapeutic intervention in fracture 
nonunion. 
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INTRODUCTION 
Background 
Fractures are the most common large-organ traumatic injuries in the general 
population, and osteoporotic fractures are the fastest growing health care problem of 
aging. In 2004, costs related to treating fractures approached $24 billion and projections 
estimate that costs of treating injuries from falls will reach $64 billion by 2020.1 While 
the processes of fracture repair after surgery are usually optimal, the healing of up to 10% 
of the estimated ~8 to 10 million fractures that occur annually in the United States is 
delayed or impaired.2  Due to repeated surgical intervention, disability of the affected 
location, and extended patient pain, patients with nonunion fractures require more 
healthcare services than patients who heal within the typical 4-6 weeks.3 Nonunion 
patients face recovery times ranging from months to years while incurring medical costs 
and requiring strong opioids for chronic pain secondary to fracture.3  Risk of nonunion is 
elevated in severe fractures, such as those that are open or have extensive comminution 
(multiple fracture fragments) on plain film, and those in locations with poor vascular 
supply, like the distal tibia or scaphoid.4 Additional risk factors for fracture nonunion 
include high body mass index, smoking, diabetic condition and alcoholism (see Table 1).4   
Table 1. Local and systemic factors predisposing and contributing to nonunion. 
Adapted with permission from Harwood 2010.5 
Predisposing Factors Contributing Factors 
Mechanical Instability Inadequate fixation Infection 
 Distraction Smoking 
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 Bone loss Certain medications 
 Poor bone quality Advanced age 
Inadequate vascularity Severe injury Systemic medical conditions 
 Excessive soft tissue stripping Poor functional level 
 Vascular injury Venous stasis 
Poor bone contact Soft tissue interposition Burns 
 Malposition or malalignment Radiation 
 Bone loss Obesity 
 Distraction Alcohol abuse 
  Metabolic bone disease 
  Malnutrition 
  Vitamin deficiencies 
 The current gold standard of therapy for nonunion fractures involves the 
application of autologous iliac crest bone grafts. However, the associated morbidity of the 
graft harvest coupled with recent advances in our understanding of fracture biology has 
spurred research into alternative therapeutic options.6 Biologics and small molecule 
therapies, such as bone morphogenic proteins (BMPs) and parathyroid hormone (PTH),7 
as well as device oriented therapeutics, such as platelet-rich plasma scaffolding,8 ceramic 
implantation,9 ultrasound delivery of osteogenic bioactive molecules,10 and application of 
mesenchymal stem cells,11 have been explored as possible avenues of therapy for fracture 
nonunion. Mesenchymal stem cell application in particular shows promise in early 
clinical trials.12,13  
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 Mesenchymal stem cells are multipotent postnatal progenitor cells originally 
isolated from bone marrow.14 Early experiments demonstrated that when these self-
renewing cells are selectively cultured and transplanted in mice they form organoids, or 
organized osseous tissue containing hematopoietic marrow with sophisticated trabecular 
framework.15  Thus, MSCs have inherent osteogenic potential and could be utilized 
therapeutically in bone modeling and repair. Additionally, in vitro studies have shown 
that MSCs can be induced to differentiate into multiple mesenchymal tissue types, 
including bone marrow stroma, cartilage, bone, adipose, muscle, tendons, and connective 
tissue.16 However, contention remains as to whether the stem cell nature (i.e. self-
renewal, multipotency) of the cell populations used in these experiments is verifiable. 
Indeed, a substantial portion of the literature treats MSCs as “medicinal signaling cells,” 
or cells that influence the cellular microenvironment via paracrine factors rather than 
cells capable of regenerating tissue. With this schema, investigators have explored the 
purported immunomodulatory potential of MSCs in a variety of disease states and 
conditions ranging from myocardial infarction to inflammatory bowel disease.17  
Statement of the Problem 
Fracture nonunion is a severe, debilitating and costly condition. As the United States 
population ages, age-related fractures are expected to increase.4 With an overall nonunion 
rate of 5 to 10 percent, while in some fractures sites and types and in conjunction with 
specific co-morbidities can approach a 50% nonunion rate, novel therapeutics warrant 
exploration. Mesenchymal stem cells and their ability to form organized osseous tissue as 
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well as their immunomodulatory effects are an attractive candidate for therapy in fracture 
nonunion.  
 
Hypothesis 
Percutaneous introduction of autologous mesenchymal stem cells will show a lower rate 
on nonunion compared to autologous iliac bone crest grafting used in the treatment of 
open comminuted tibia fractures treated by locking intramedullary nails.  Progression of 
healing and nonunion will be assessed using modified Radiological Union of Tibia 
(mRUST) scoring system over the 9 months and a generalized wellness score SF-12 1.   
 
Objectives and specific aims 
This study is designed to evaluate the therapeutic use of mesenchymal stem cells in 
fracture nonunions of the lower extremity long bones. The current gold standard of 
therapy is iliac crest bone autograft. However, this is associated with significant 
morbidity to the donor site.18 By using concentrated bone marrow aspirate, morbidity 
from the harvest can be reduced. Additionally, assessment of patient-centered outcomes 
allows for a more holistic comparison of the two treatment paradigms.  
The specific aims of this study are as follows. 
1) The standard time of nonunion will be assessed at 9 months for a long bone of 
the lower extremity. Nonunion will be assessed radiographically using a modified 
Radiological Union of Tibia (mRUST) scoring system over the 9 months’ period at each 
patient recall. Scoring will be in a blinded manner by five independent orthopedic trauma 
 5 
surgeons with an assessment of the rater intra-class correlation coefficients (ICC) of the 
reads.  
2) Overall progression of healing will be assessed using a generalized wellness 
score SF-12  Secondary criteria that will be examined include reoperation and general 
complication rates as well as regain of function.  
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REVIEW OF THE LITERATURE 
Overview 
Nonunion is defined as the cessation of all reparative processes of healing without 
bony union in 9 months since the time of frature.19 In the United States alone, an 
estimated 100,000 fractures go on to nonunion each year.20 The likelihood of fracture 
nonunion is dependent on both the fracture per se and the patient. Risk factors for 
nonunion include advanced patient age, genetic predisposition, metabolic disease (i.e. 
diabetes mellitus types 1 and 2), obesity, osteoporosis, rheumatoid arthritis, excessive 
alcohol use, cigarette smoking, and certain medications like NSAIDs and some 
antibiotics.  Additionally, the type of trauma, fracture, site of injury, and treatment 
modalities all influence fracture outcomes (please refer to Table 1.).21  
 Nonunion fractures have been shown to have a negative impact on not only 
patients’ physical health, but also their mental well-being.22   Repeated surgeries, 
protracted pain secondary to the fracture, and increased medical costs contribute to the 
burden fracture nonunion patients carry.3  A study of 237 patients with tibial shaft 
fracture nonunions compared Short Form (SF)-12 (a questionnaire designed to assess 
global health) scores against previously published scores for patients with orthopedic 
conditions, chronic medical conditions, and the general United States population.  The 
results of the study showed physical component summary (PCS) scores (an indicator of 
global physical health) for the nonunion patients averaged well below the tenth percentile 
of the United States population (mean nonunion PCS score 27.4 ± 6.7, US mean PCS 
score 50 ± 10, p<0.001). Additionally, average mental component summary (MCS) 
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scores (an indicator of global mental health) of nonunion patients were found to be below 
the twenty-fifth percentile of the United States population (mean nonunion MCS score 
42.3 ± 7.1, US mean MCS score 50 ± 10, p=0.008).22  Taken together, this data 
quantifiably demonstrates the physical and mental toll nonunion has on patients. This 
data highlights the need for effective therapies in the setting of delayed and nonunion 
fractures. 
Clinical Course of Therapy 
Fractures occur when an applied load is greater than the load-bearing capacity of 
the bone. The greater the applied load (i.e force of the trauma), the more severe the 
fracture and the greater the risk of nonunion.21 If the epidermis is breached (i.e. an open 
fracture) the patient is at an elevated risk of infection, particularly infection of the bone 
(osteomyelitis). Infection of the fracture site not only perturbs the physiologic 
mechanisms of fracture repair but also is a significant cause of mortality in patients with 
open fractures.23  Thus, current clinical practice dictates empiric intravenous antibiotics 
and prompt irrigation and debridement of open fractures.24  Failure to clear infection of a 
fracture site can contribute towards risk of nonunion, systemic illness, amputation of the 
affected limb, and even death.24 
Once an acute fracture patient is hemodynamically stable and acute 
complications, such as neurovascular injury, are ruled out, the necessity of reduction 
should be assessed. Reduction is indicated in fractures with significant displacement or 
angulation.  If severely angulated or displaced fractures are allowed to heal without 
reduction, the healed bone will be deformed and may limit joint motion leading to 
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disability. The goal of reduction is to bring the fracture edges as close to normal anatomic 
alignment as possible.  Reduction can be performed in an open or closed manner. Closed 
reduction involves the application of traction to externally manipulate displaced bone 
fragment into anatomic position. This can be a painful procedure and is typically 
performed under conscious sedation.  Stabilization after closed reduction typically 
involves casting but may also include percutaneous pinning and splinting. Open reduction 
may be necessary in fractures with more severe angulation, displacement, and 
comminution and consists of surgical apposition of the fracture edges under general 
anesthesia. Open reduction is always stabilized with internal fixation, in which 
intramedullary nails, screws, and plates bridge the fracture gap, maintaining alignment 
and providing mechanical stability. If the implants used for mechanical fixation are not 
stable and significant movement occurs across the fracture gap, hard callus formation is 
inhibited and risk of nonunion is increased.25  Thus, care must be taken to ensure 
sufficient stability across the fracture site. However, surgical choice of internal hardware 
and technique are fracture and patient dependent. 
 Postoperatively, patients should be closely monitored for signs of acute 
compartment syndrome, osteomyelitis, or deep vein thrombosis (venous 
thromboembolism prophylaxis should begin as soon as is feasible). Delay in recognizing 
the signs of these complications can lead to death or significant morbidity, including 
sepsis and amputation. Additionally, adequate pain control is an important aspect in the 
clinical management of fracture patients. Nonsteroidal antinflammatory drugs (NSAIDs) 
have been associated with increased risk of nonunion,21 though a systematic review of the 
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literature detected no increase in risk among high quality studies.26 Clinically, patients are 
typically counseled to avoid NSAID use and take acetaminophen for mild to moderate 
pain. However, patients with severe fractures often require opioids for sufficient 
analgesia.  
Normal Processes of Fracture Healing 
  Once proper bony alignment and stabilization has been achieved via interventions 
discussed above (see Clinical Course of Therapy), the physiologic process of fracture 
healing takes place in and around the fracture site. While this process is gradual and 
continuous, it can be conceptually defined in three overlapping stages: (1) the early 
inflammatory stage, (2) the repair stage, and (3) the late remodeling stage.27  Immediately 
following the fracture and resulting damage to adjacent vascular structures, a cascade 
begins in which transforming growth factor-β (TGF-β), platelet-derived growth factor 
(PDGF), vascular endothelial growth factor (VGEF), interleukins-1 and -6 (IL-1 and IL-
6), bone morphogenetic proteins (BMPs), tumor necrosis factor-α (TNF-α) and other 
bioactive factors are released promoting angio- and osteogenesis.28  Compromise of 
vascular structures around the fracture gap leads to extravasation and hematoma 
formation. Macrophages, monocytes, and other phagocytic cells clear the surrounding 
tissue of debris, while activated endogenous MSCs converge on  the fracture site via 
chemotactic mechanisms.28 The hematoma already has mesenchymal stem cells capable 
of osteogenic potential, as evidenced by early studies showing transplantation of mouse 
fracture hematoma into muscle to form new bone by endochondral ossification.5 Clotting 
factors transform the hematoma into a fibrinous thrombus which in turn matures into 
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granulation tissue as angiogenesis leads to capillary invasion of the clot.  This weak 
healing construct has a tensile strength, the force required to pull until it breaks, of about 
0.1 MPa (normal bone is 130 MPa).29 While the timeframe of this process is unique to 
each patient and fracture, resorption of the 1 to 2 mm of bone at the fracture edges is 
radiographically apparent 5 to 10 days following the injury.30  
The second stage of the fracture healing process involves the formation of soft 
callus, fibrocartilage. Chrondrocytes derived from mesenchymal progenitors produce 
hyaline cartilage rich in Type 2 collagen, which bridges the fracture gap creating 
mechanical stability and a template for future ossification.28 Meanwhile osteoblasts 
synthesize intramembranous bone formations at the periosteal surfaces. The combination 
of these structural elements creates a semi-rigid construct with a tensile strength between 
4 and 19 MPa, roughly the same tensile strength as rubber (15 MPa).29  Of note, in 
fractures with direct apposition of fracture edges hard callus can form without an 
intervening soft callus template.28 
 The third stage of healing, primary bone formation, entails vascularization and 
ossification of the soft callus forming hard callus. Osteoblasts synthesize mineralized 
bone matrix with concomitant vascularization, forming the crude architecture of the hard 
callus.28 The hard callus is rigid, with a tensile strength of 130 MPa29, approximately 32 
times as strong as the soft callus construct. While at this point the fracture is clinically 
healed, physiologic remodeling will continue to take place as the woven bone bridging 
the fracture site is broken down by osteoclastic activity and replaced with lamellar 
bone.29  
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The fracture healing process described above typically takes 4 to 6 weeks for 
simple fractures.30 Patients are then evaluated for evidence of union, a determination 
complicated by the fact that there is no diagnostic “gold standard.”  Several standardized 
methods of evaluating radiographs for evidence of union have been developed, including 
the radiographic union scale in tibial (RUST) fractures, discussed below.31 However, 
inter-observer correlation is poor and may underestimate healing progress.32 Therefore, 
determination of union is a clinical decision based on both radiographic evidence and 
clinical gestalt30  
Fracture Healing in Nonunions: Causes and Therapies 
Fractures as a result of extreme mechanical force often have radiographic features 
of comminution (multiple fracture fragments), significant displacement, and angulation. 
Even with good surgical management, fractures with these features tend towards delayed 
union, malunion, and nonunion.25 Delayed union denotes lack of clinical union at 6 
months but with radiographic or clinical evidence of continued improvement.33 
Malunion, on the other hand, refers to a healed fracture that is not in anatomic alignment, 
resulting in a shorter bone length, disruption of joint movement, or physical deformity.19 
If 6-8 months pass and no improvement is seen on serial radiographs and in clinical 
examinations, the clinician should assess whether the fracture is a delayed union or 
nonunion. While the FDA classifies nonunion at 9 months, in clinical practice the time at 
which a fracture is determined as nonunion is not well defined due to the inherent 
variability in fracture healing times.19 Delayed union denotes lack of clinical union at 6 
months but with radiographic or clinical evidence of continued improvement.33 Thus, 
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delayed unions will likely continue to heal, albeit at a protracted rate, whereas nonunions, 
by definition, have stopped all healing processes and will not result in union without 
additional intervention.19 
 Nonunion fractures can be broadly classified as either hypertrophic or atrophic.19 
Hypertrophic nonunion fractures are thought to have sufficient vascular supply but lack 
mechanical stability. Radiographically, hypertrophic nonunion fractures are often horse-
show or elephant-foot shaped with decreased callus formation.19 Atrophic nonunion 
fractures, on the other hand, are associated with poor vascular supply despite sufficient 
stabilization. Lack of bony bridging with little callus formation can be observed on 
radiographs of atrophic nonunion fractures.19 Due to the biological and mechanical 
distinctions between these differing nonunion fracture patterns, treatments are different 
and tailored to address the underlying deficiency.  
Hypertrophic nonunion fractures have inadequate mechanical stability and, 
therefore, treatment aims to increase stability across the fracture site.  Stability is 
achieved through fixation, either internally with nails and screws or externally with casts 
and immobilization devices. With proper stability, ossification and vascularization of the 
callus can occur without the need for grafting or osteobiologic intervention.19 
Atrophic nonunion fractures are more challenging to treat. The current gold 
standard of therapy involves the application of bone autograft, typically harvested from 
the iliac crest, into the fracture gap.6 The graft is then incorporated into the local tissue, 
stimulating angio- and osteogenesis. Concurrent mechanical stabilization of the fracture 
is paramount, typically with internal fixation applied during surgical application of the 
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graft.19  Choice of bone graft is surgeon-dependent, though not all bone grafts are equally 
efficacious. Cancellous bone grafts are superior to cortical bone grafts in cellular density, 
rate of revascularization, and resorption and remodeling time.6 Bone autograft remains 
the gold standard in part due to its osteogenic, osteoinductive, and osteoconductive 
properties.19 Briefly, osteogenesis entails new bone formation, such as in the reparative 
process described above. Osteoconduction refers to graft scaffolding for endogenous 
osteoblasts to use as a framework for osteogenesis. Biologic stimulation of 
osteoprogenitor cells to differentiate into osteoblasts is known as osteoinduction. These 
three properties, osteogenesis, osteoconduction, and osteoinduction, represent the three 
physiologic mechanisms necessary for bone repair to occur.6 Of the current therapeutic 
options for atrophic nonunion, bone autograft remains the only one to exhibit the three 
physiologic properties per se.6 However, iliac crest bone graft involves a high rate of 
complications and significant morbidity at the donor site, and thus is only undertaken 
when strictly indicated.18,34 
Alternative therapeutic options for fracture nonunion include low-intensity pulsed 
ultrasound (LIPUS), bone marrow aspirate, platelet-rich plasma, recombinant bone 
morphogenic proteins, demineralized bone matrix, ceramics, allograft bone, and 
mesenchymal stem cells. While early randomized controlled trials of LIPUS use in 
nonunions appeared promising,35 a recent meta-analysis did not show that LIPUS reduces 
the incidence of fracture nonunion.36  Given that LIPUS purportedly works via 
osteoinductive mechanisms,37 it is perhaps unsurprising that LIPUS therapy alone can be 
insufficient for recalcitrant nonunions.  Similarly, platelet-rich plasma (PRP) works via 
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osteoinductive mechanisms and can be obtained in an autologous manner via relatively 
non-invasive peripheral phlebotomy. However, the osteoinductive effect of the 
concentrated growth factors found in PRP has failed to translate into improved clinical 
outcomes compared with bone morphogenic proteins.38 Bone morphogenic proteins 
(BMPs) are involved in the osteoinduction of endogenous osteoblasts. Commercially 
available recombinant BMPs have been studied in conjunction with surgical debridement 
and stabilization,39,40 but their efficacy cannot be fully assessed because no appropriate 
control groups were available for comparison in these studies.6     
While LIPUS, PRP, and BMPs are osteoinductive, they are not osteoconductive.  
That is to say, application of these therapies may induce osteoblastic activity in 
endogenous cells, but without a framework with which to conduct this activity, 
osteogenesis may not take place. Ceramics such as calcium sulfate and hydroxyapatite 
have been explored as an osteoconductive scaffold in fracture repair. However, while 
these synthetic “spacers” can be used in conjunction with osteoinductive elements, they 
are rarely used alone.6 Demineralized bone matrix (DBM), on the other hand, is both 
osteoinductive and osteoconductive.  By acidifying allograft bone, minerals are 
chemically removed while the collagen, non-collagenous proteins, and growth factors 
remain. The resulting DBM can be used to stimulate new bone formation 
(osteoinduction) as well as provide a collagenous matrix for osteogenesis to take place 
(osteoconduction).6  However, DBM still relies on endogenous osteoblasts for 
osteogenesis.  
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Allograft bone is very similar to DBM and depending on the preparation can be 
both osteoconductive and osteoinductive. However, allograft has an inherent potential for 
graft vs host disease, in which the recipient’s immune system rejects the donor material.41 
Bone marrow aspirate, on the other hand, is autologous and therefore will not precipitate 
an immune response. Composed of hematopoietic and mesenchymal stem cells as well as 
growth factors, bone marrow aspirate has been shown to be osteogenic, osteoinductive, 
but not osteoconductive.6 By centrifuging the bone marrow aspirate, a process that can be 
done while in the operating room, the stem cells and osteobiologic factors can be 
concentrated, thus theoretically enhancing their therapeutic effect.42  
While each of these therapeutic modalities has potential utility in the treatment of 
nonunion fractures, the unique biology of mesenchymal stem cells makes them an 
attractive candidate for therapeutic application in this setting. 
Brief Overview of Stem Cell Biology 
Since the successful cultivation of mouse stem cells in 1981, stem cells have been 
the focus of extensive scientific research.43 Stem cells have the infinite capacity to self-
renew (replicate) and ability to differentiate into specific cellular lineages, a phenomenon 
referred to as potency.  Some stem cells, such as embryonic stem cells, are pluripotent, or 
able to differentiate into any cell type in the body.44  Other stem cells, such as 
mesenchymal stem cells (MSCs), are multipotent, or able to differentiate into a certain 
subset of cells, such as bone, cartilage, and fat.  The discovery of stem cells’ ability to 
differentiate into a multitude of different specialized cells inspired the search for ways in 
which stem cells could be used clinically.  In pursuit of this search the field of 
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regenerative medicine was born. Regenerative medicine aims to utilize stem cells to 
reconstruct tissue injured by disease or trauma.45 However, nascent stem cell research 
was plagued with ethical, moral, political, and legal quandaries as this new science 
brought forth new questions and difficulties.44 
Research on stem cells arose not from studies of embryonic development, but 
from careful characterization of teratomas, or abnormal gonadal growths.44  These tumors 
are comprised of teeth, skin, hair, sebaceous material, and more adult tissues all arranged 
in a haphazard conglomerate. Work by Leroy Stevens and Barry Pierce in the 1950s and 
1960s demonstrated the existence of a particular cell within teratomas capable of 
differentiating into multiple adult cell types, now referred to as a multipotent stem cell.46  
Largely thanks to the foundational research on embryonic carcinoma cells derived from 
teratocarcinomas, the study of mouse embryonic stem cells advanced rapidly.  Isolated 
mouse embryonic stem cells were successfully tested in their ability to form germline 
chimaeras following insertion into a tetraploid blastocyst.44  Germline chimerism in 
combination with gene targeting by homologous recombination opened the door for 
transgenetic research. For the first time, genes could be selectively altered, or “knocked 
out,” in whole organisms.  The development of gene modification in mice was so 
transformative to the research landscape the 2007 Nobel Prize in Physiology or Medicine 
was awarded to the team who developed the method.47 
While embryonic stem cell research continues to be investigated today — 51 
“embryonic stem cell” trials are listed on clinicaltrials.gov — more attention is focused 
on adult stem cell research in clinical therapy with 6,061 “adult stem cell” trials listed on 
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clinicaltrials.gov.48,49  The overwhelming emphasis on adult stem cell research may be 
due to the politicized and inflammatory nature of embryonic stem cells, but it also may be 
due to the many advantages of using adult stem cells therapeutically. 
 The hematopoietic stem cell (HSC) was the first adult stem cell described in the 
literature. This self-renewing cell type resides in the sinusoids of the bone marrow and 
can differentiate into any hematopoietic cell.50 Seminal experiments in the 1950s detailed 
the capacity for self-renewal and multipotency of HSCs.  Administering bone marrow 
cells from healthy mice intravenously to mice with radio-ablated bone marrow 
demonstrated HSCs have the ability to restore the complete hematopoietic capacity of 
animals with non-functional bone marrow.51,52   More than half a century later this in vivo 
serial reconstitution experimental design remains the gold standard for demonstrating 
capacity for self-renewal, though in vitro methods have become commonplace in the 
literature.53    
 Hematopoietic stem cells were once thought to be the only type of adult stem 
cells, but we now know of many more stem cell types, including neuronal,54 intestinal,55 
mesenchymal,14 satellite,56 and epidermal.57  These adult stem cells can be multipotent or 
unipotent but are not pluripotent.  Therapeutic applications of adult stem cells are 
generally employed in the organ system from which they were isolated. For example, in 
one study mesenchymal stem cells (MSCs) isolated from dental pulp produced dentin and 
dental pulp in vitro, whereas bone marrow-derived mesenchymal stem cells (BM-MSCs) 
formed heterotopic bone tissue.58 Thus, adult stem cells have differentiation tendencies 
based on their tissue of origin. This has important clinical and experimental implications 
 18 
when considering where to isolate stem cells from.  For example, in orthopedic 
interventions BM-MSCs are preferred over MSCs originating from other tissue types.53  
Mesenchymal stem cells (MSCs) are elusive to define partly due to the multitude 
of names attributable to them. For example, Dr. Arnold Caplan who first coined the term 
mesenchymal stem cells in 1991, now refers to them as Medicinal Signaling Cells.14,59 
Other labels bestowed on this population of cells include bone marrow stromal cells, 
perivascular stem cells, mesenchymal stromal cells, multipotent mesenchymal stem cells 
and postnatal skeletal stem cells.53,60   The Medical Subject Heading (MeSH term) 
assigned to this group of cells by Pubmed is “Mesenchymal Stromal Cells,” though they 
were indexed as “Mesenchymal Stem Cells from 2006-2010.61  Given their capacity for 
self-renewal and potential for multi-lineage differentiation (i.e. stem-cell like nature) into 
many mesenchymal cell types (cartilage, bone, adipocytes, fibrous tissue, smooth muscle, 
cells, and myelosupportive stroma), as well as the historical usage of the term in the 
literature, this work will use the term mesenchymal stem cell (MSC), though the author 
acknowledges the validity of other labels.53  
The first work on mesenchymal stem cells was performed in 1966 by Friedenstein 
et al., who showed that a sub population of cultured bone marrow cells formed avascular 
heterotopic bone fragments in vitro.62  This seminal experiment demonstrated the 
existence of a multipotent nonhematopoeietic stem cell within postnatal bone marrow 
stroma. In other words, this experiment demonstrated the innate osteogenic potential of 
certain bone marrow cells. Isolation of these osteogenic bone marrow cells from the 
hematopoietic cells also found in the bone marrow could only be achieved through 
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culture methods, as cell sorting and immunological techniques were not yet available. 
Stromal bone marrow cells, or cells part of the physical and functional framework of the 
bone marrow, adhere to plastic, and thus could be isolated from hematopoietic cells in 
culture (Friedenstein & Kuralesova 1971). By plating bone marrow stromal cells at a 
clonal density, cells capable of density-independent growth (an indicator of propensity 
for growth)53 could be isolated and soon became known as colony-forming units-
fibroblastic (CFU-Fs) (Castro-Malaspine et al. 1980). Roughly 10-20% of these CFU-F 
colonies are multipotent, as evinced by in vivo studies demonstrating heterotopic ossicle 
formation (complete with bone cells, stroma, adipocytes, and fibroblasts) with CFU-F 
transplantation in mice.63 Thus, a clonal subset of bone marrow stromal cells not only has 
osteogenic potential, but multipotency as well. 
Beyond multipotency, stem cells should also demonstrate the capacity for self-
renewal. In hematopoietic stem cells (HSCs), self-renewal was proven by using (1) a 
defined surface phenotype of HSCs, and (2) serial transplantation as an in vivo assay.15 
While studies were performed characterizing the immunophenotypic profile of cultured 
MSCs,14,64 direct identification of mesenchymal stem cells from in situ to in vitro eluded 
all attempts.  However, in 2007 Sacchetti et al. showed that CD146+ cells matched 
clonogenic progenitors, pericytes in situ, and were able to generate complete organoids, 
including the hematopoietic microenvironment.65 The CD146+ pericytes could then be 
serially transplanted.66 This data confirms the capacity of MSCs for self-renewal, as well 
as identifies MSCs as pericytes.  
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The evidence listed above supports the idea of a self-renewing MSC which 
resides in a perivascular niche and is capable of differentiating into cartilage, bone, 
adipocytes, fibrous tissue, smooth muscle cells, and myelosupportive stroma.53 This 
evidence is distinct from a substantial portion of the literature espousing the trophic or 
immunomodulatory properties of mesenchymal stem cells.  According to the trophic 
model of MSC biology, MSCs are pericytes which are capable of differentiating into 
osteocytes, chondrocytes, myoblasts, stromal cells, fibroblasts, adipocytes, and other 
connective tissue cell types.17 However, studies arguing for the capacity of MSCs to 
differentiate into these varied and diverse lineages utilize a definition of MSCs that does 
not include validation of the stem-cell nature of the cells used. Instead, these studies are 
based on a position statement the International Society for Cellular Therapy (ISCT) put 
forth outlining minimal criteria for defining multipotent mesenchymal stromal cells.  This 
report stated that MSCs are defined by (1) adherence to plastic, (2) specific surface 
antigen expression, and (3) multipotent differentiation potential.67 The defining surface 
antigens are CD105, CD73 and CD90, markers which must be expressed on 95% or more 
of a MSC population isolated by flow cytometry. Additionally, these cells must lack 
expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA class II, thus 
excluding cells of hematopoietic lineage. Using this minimal criteria, studies 
demonstrated the isolation of “MSCs” from brain, spleen, liver, kidney, lung, bone 
marrow, muscle, thymus, and pancreas – virtually all post-natal organs and tissues.60  
Thus, it became widely accepted that MSCs are pericytes which reside in every tissue. 
Coupled with the observation that cells with pericyte characteristics respond to local 
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injury and participate in the wound healing process, MSCs were characterized as trophic 
mediators of local inflammatory processes.17  
Confabulation between ISCT-defined MSCs, pericytes, and true MSCs capable of 
self-renewal as detailed above, led to the study of the therapeutic potential of MSCs in a 
variety of conditions, ranging from myocardial infarction to inflammatory bowel 
disease.68 Industry investment in MSC application with concomitant contribution to the 
literature distorted the careful characterization of a self-renewing, multipotent 
mesenchymal stem cell found in the bone marrow to a trophic cultured “drugstore” 
capable of delivering therapeutic potential in almost any application.68 Without stringent 
verification methods of stem cell biology in cultured MSCs, these studies espousing the 
trophic and immunomodulatory methods of MSCs must be considered with a high degree 
of skepticism.15   
Existing Research 
The therapeutic application of mesenchymal stem cells (MSCs) in orthopedic 
conditions has been studied in human clinical trials since 1986.  Connolly and Schindell 
demonstrated that in 100 patients with tibial nonunion application of 100-150 mL of 
marrow osteoprogenitor cells resulted in better outcomes compared with standard open 
iliac crest grafting.69  This pioneering study opened the door for a series of investigations 
into different preparations of MSCs in varied orthopedic settings. 
Garg et al. showed that in 20 cases of nonunion of long bones (15 tibia, 3 
humerus, and 2 ulna) percutaneous autogenous bone marrow grafting of 15-20 mL of 
bone marrow resulted in union in 17/20 cases.70 This study opened the possibility of 
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nonsurgical resolution of fracture nonunion. A trial in 2005 of 20 cases of tibial nonunion 
showed that percutaneous autogenous bone marrow grafting (15 mL of bone marrow) 
resulted in 15/20 union with 4 patients exhibiting no sign of union.71 This study builds 
upon the earlier work by Garg et al. and proves that percutaneous injection of bone 
marrow is a simple, safe, inexpensive, and effective therapy in fracture 
nonunion.72However, these studies employed bone marrow aspirate, a mixture of both 
hematopoietic and mesenchymal stem cells as well as other factors, so the therapeutic 
effect of MSCs alone cannot be ascertained from this study. 
A study in 2005 by Hernigou et al. attempted to quantify the therapeutic 
contribution of MSCs by correlating them to CFU-Fs derived from concentrated bone 
marrow aspirate.42 This study found that 53/60 atrophic tibial nonunions inoculated with 
concentrated bone marrow aspirate achieved union.  Beyond demonstrating the 
therapeutic effect of this intervention, this study also compared computerized 
tomography scans with the concentration of CFU-Fs in the concentrated bone marrow 
injected for each patient. They found that there was a positive correlation between the 
volume of mineralized callus at four months and the number (p=0.04) and concentration 
(p=0.01) of CFU-Fs in the graft. However, it should be noted that not all CFU-Fs are 
clonal populations of MSCs, as only a portion of them can form ectopic bone when 
transplanted.53 Additionally, the range of cells applied in this study varied greatly (60-
6120 progenitors/cm(3)),42 highlighting the necessity for a standardized concentration 
technique. 
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In 2001, Quarto et al. bridged the gap between the laboratory and the operating 
room and demonstrated that demonstrates that ex vivo expanded MSCs can be used with 
an osteoconductive scaffold to heal large bone defects.73 Bone marrow cells were 
expanded in culture, seeded on hydroxapatite ceramic scaffold, and implanted at the 
lesion sites. Mechanical stability was ensured by external fixation. This small case study 
found that cultured MSC application was safe and effective in 3 patients with large bone 
diaphysis defects.73 It should be noted, however, that while the cultured MSCs in this 
study were shown to form ectopic bone (i.e. osteogenic capacity), they were not shown to 
be self-renewing via serial transplantation. Additionally, as this was a small case study, 
more patients and appropriate controls would be needed to prove the therapeutic effect of 
MSCs. 
Kitoh et al. enhanced the osteogenic capacity of culture-expanded bone marrow 
cells (not specifically MSCs) with the concomitant use of PRP in femoral and tibial 
lengthening.74 Bone lengthening, or distraction osteogenesis, entails fixation of a fracture 
without apposing the fracture ends, allowing the callus to form across the fracture gap 
thus preserving limb length. The healing index is a widely used parameter employed to 
quantify the quality and speed of bone formation and is measured in distraction-
consolidation time (DCT), or time to bony stability, per cm (DCT/cm). In this study, they 
found that the healing index of the bone marrow cell and PRP treated bones (n=51) was 
significantly lower than the control group that received no cell therapy (n=60). However, 
this study was performed in the pediatric population (average age 15.0 ± 3.21 years) and 
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thus generalizability to the adult population is questionable. Additionally, this study was 
retrospective in design, and thus inherently biased. 
A multicenter open randomized clinical study in 2009 aimed to assess autologous 
cultured osteoblast injection compared to no treatment in 64 patients with long bone 
fractures with poor callus formation six weeks after surgery.75 They found that osteoblast 
injection accelerated the healing process and was not associated with specific patient 
complications. This study emphasizes the utility of osteoprogenitor cells in accelerating 
fracture healing. However, fracture healing was assessed by callus formation score as 
determined by two blinded radiologists. As noted above, purely radiographic evaluation 
of fracture healing without clinical correlation is insufficient in evaluating fracture 
union.24 
A 2013 randomized prospective preliminary study demonstrated that patients with 
distal tibia fractures MSCs and PRP on demineralized bone matrix (DMB) vs standard of 
care had faster union rates.12 Twenty-four patients were randomized into either minimally 
invasive intervention (MII) or control. The intervention involved aspirating iliac crest 
bone marrow and peripheral blood to yield MSCs and PRP, respectively. The MSCs were 
isolated via CD105+ immunoselection and combined with PRP on a DMB scaffold and 
injected under fluoroscopic guidance into the fracture site. The control group underwent 
watchful waiting. The median time to union was twice as long in the control group (3 
months) as compared to the MII group (1.5 months).  However, because neither group 
had complications (i.e. delayed or nonunion), the primary outcome of the study was never 
truly assessed. That being said, a strength of this study involved the use of biologic 
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controls. Graft material from each graft was implanted in immunodeficient mice, 
demonstrating in vivo bone formation. Thus, by combining the osteogenic potential of 
MSCs, the osteoinductive properties of PRP, and the osteoconductive scaffold of DMB, 
this study effectively replicates the bone healing properties of autograft. 
In a similar study, Giannoti et al. isolated bone marrow derived MSCs from 8 
patients suffering from atrophic pseudoarthrosis (soft callus formation without hard callus 
ossification) of the upper limb and expanded the cells ex vivo, osteo-differentiated them 
in autologouos-based culture conditions, then embedded the MSCs in autologous fibrin 
clots. The patients were then evaluated for fracture healing for both short and long term 
follow-up.  The study found that this autologous treatment approach was safe and 
effective and resulted in successful clinical and functional outcomes for all 8 patients.13 
This study, while small in size, demonstrates not only good clinical outcomes for 
debilitating pseudoarthrosis, but also good laboratory practice in using autologous culture 
conditions and agents. However, this study did not have an adequate control group or any 
blindedness in recruitment and intervention, and must be evaluated with these drawbacks 
in mind. 
More recently, a 2015 retrospective study of 86 diabetic patients with distal tibia 
and ankle nonunions treated with percutaneous injection of bone marrow mesenchymal 
stem cells resulted in fewer complications and improved healing rates compared to the 
control group treated with standard bone iliac crest autograft.76 Bone marrow was 
aspirated from the iliac crest and treated by using a cell separator. The number of MSCs 
present in the bone marrow concentrate was inferred from the number of CFU-Fs. The 
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study found that of the 86 patients to receive MSC therapy, 70 achieved union (82.1%) 
compared to 53 of the 86 patients treated with iliac crest bone graft (62.3%). The 
associated donor site morbidity was also assessed in this study. Both minor and major 
complications as a result of donor site morbidity were significantly lower (p=0.01, 
p<0.01, respectively) in the MSC group compared to the bone iliac crest group. This 
study is limited by its lengthy recruitment period (1990-2012) and small sample size, 
though the authors argue the sample size appears sufficient. Additionally, this study 
examined bone healing in diabetic patients and thus the results may not be generalizable 
to the larger population. However, this study effectively demonstrates improved healing 
rates in fracture nonunions and fewer donor site complications in patients treated with 
MSCs compared to iliac crest bone graft. 
Taken together, these studies show that application of MSCs with or without 
concomitant osteobiologic therapy is safe and effective. However, the method of MSC 
isolation, utility of ex vivo culture expansion, inclusion of osteoconductive scaffold, and 
route of administration are all important variables for which there is no unified 
consensus. 
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METHODS 
Study design 
 This study will be a multicenter non-randomized controlled study of percutaneous 
autologous mesenchymal stem cells (MSCs) vs autologous iliac crest bone graft in 
patients with open tibia comminuted fractures treated with a locking intramedullary rod 
that failed to heal within 9 months. 
Study population and sampling 
The patients will be recruited over a period of five years from the outpatient 
orthopedic clinics of Boston Medical Center, Brigham and Women’s Hospital, and 
Massachusetts General Hospital. Without publicly available data relating the volume of 
fracture nonunion treatment at these institutions, this recruitment period is based on 
incidence of fractures requiring an inpatient level of care at a similar sized institution77 
and the assumption that 5% of those fractures will go on to nonunion. Thus, the estimated 
volume of fracture nonunions seen at all three hospitals is 56 per year.  Inclusion criteria 
include: open tibia comminuted fractures treated with a locking intramedullary rod; 
evidence of fracture nonunion 9 months after fracture; the patient is able to understand 
the nature of the study; and informed written consent is provided by the patient. 
Exclusion criteria include: age greater than 75; age less than eighteen; legally dependent; 
signs of infection; positive serology for HIV; pregnancy or breast-feeding; personal 
history of cancer; immunosuppression; and surgical intervention within the last 9 months.  
Fracture nonunion will be determined if at 9 months from the injury no radiographic or 
clinical signs of healing at the fracture site are evident to the practitioner.  
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 The estimated sample size will be 134 fracture nonunions per arm using sample 
size calculations that assume an 85% union rate in the MSC arm and a 70% union rate in 
the iliac crest bone graft arm given 80% power and 5% significance. These rates are 
based on the 2015 Hernigou et al. study with the assumption that a mixed patient 
population will have slightly superior healing rates compared to a solely diabetic 
population. Thus, a total of 268 nonunion fractures are needed to power our study and our 
recruitment period is estimated to accrue 280 patients over five years, accounting for 
some loss to follow-up. 
 
Treatment 
The eligible study population will be informed of the associated risks and benefits 
of both procedures and the rationale for the investigation will be discussed and informed 
consent approved by the hospital will be signed. Given that the two interventions detailed 
herein have different morbidities to the donor sites, it is likely that subjects will discern 
which treatment they received. Thus, this is not a blinded study. However, the patients 
will be randomized to one of the two treatment arms using a computer generated model.  
The autologous iliac crest bone graft group will undergo standard graft harvest 
procedure. Under general anesthesia, a 4-5 cm incision will be made just below the 
anterior iliac wing. The overlying tissue will be resected to the periosteum, at which point 
a small 2x2 cm area on top of the crest will be stripped using a periosteal elevator. Using 
a rongeur, a small window, approximately 1.5 x 1.5 cm on top of the crest will be formed. 
A curette will be used to extract cancellous bone from between the inner and outer tables 
 29 
and local anesthetic will be applied to the donor site. The cancellous bone graft harvested 
from the anterior iliac crest can then be packed into the fracture gap using surgeon-
specific and case-specific methods. 
 The percutaneous autologous MSC group will undergo bone marrow aspiration.  
The procedure detailed herein was developed by the Gerstenfeld laboratory at Boston 
University School of Medicine.  Bone marrow will be aspirated from the anterior iliac 
crest using a single 5 mm incision. After deep insertion of a beveled Jamshidi needle 6 to 
8cm long and 1.5mm in diameter into trabecular bone, marrow will be aspirated into a 
precoated 30 ml syringe that have been rinsed with a buffer solution containing 400mL of 
phosphate buffered saline, 25 000 units of heparin and 100 ml of human albumin to avoid 
clotting. The needle will be moved toward the surface through the same insertion site, 
with successive aspirations made by turning the needle 90 degrees after each aspiration, 
and retracting the needle 1 cm after 2 aspirations at 90 degrees to each other. Using this 
method, only 5 cc of bone marrow will be aspirated from any one site, in order to prevent 
dilution with peripheral blood in the bone marrow space. The aspirate will then be 
transferred into a bone marrow collection kit to obtain a final volume of 120 ml of bone 
marrow aspirate. Nucleated cell and platelet counts will be obtained for every sample pre 
and post concentration. A final sample of 20 ml is obtained for every centrifugal 
concentration. All samples are sent for routine bacterial and fungal cultures. Two 
milliliters of every sample will be assessed by FACS analysis (see below). 
With regards to the bone marrow concentrate injection, a 1 cm incision will be 
made through the skin and fascia at the level of the fracture site. Under fluoroscopic 
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guidance, a guide wire will be inserted through the cortex of the bone, and into the 
fracture site. A cannulated drill will be directed over the guide wire to within 2mm of the 
cortical surface. The guide wire will then be withdrawn and 2 ml of water soluble 
contrast (Visipaque) will be injected through the drill to confirm the area through which 
the injected bone marrow will spread. Twenty ml of concentrated bone marrow will then 
be injected into the fracture site, slowly over a period of approximately 3 minutes. Both 
incisions are closed with absorbable sutures. 
Study variables and measures 
The primary outcomes are radiographic and clinical features of union. 
Radiographic evidence from the time of recruitment and 9 months post-intervention will 
be evaluated by five independent radiologists in a blinded manner. They will score the 
results according the modified radiographic union score for tibial (mRUST) fractures 
scoring system. The mRUST scoring system has demonstrated slightly higher intraclass 
correlation coefficient (ICC) as compared to the RUST scoring system, indicating greater 
inter-observer reliability with this tool.78 The radiographic evidence will be evaluated as 
either union or nonunion by calculating the mean mRUST score from all five 
radiologists. A mean mRUST score above 11 will be defined as union and below 11 will 
be nonunion.  
Short-Form 12 (SF-12) is a questionnaire developed from the Medical Outcomes 
study. The aim of the questionnaire is to measure 8 domains of health-related quality of 
life. Both physical and mental summary scores can be obtained. Each health domain is 
scored separately from 0 to 100. This self-administered questionnaire is used widely in 
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orthopedic studies and has high test repeatability.79 Clinical evidence as documented in 
the electronic record at the time of follow up will be evaluated by an independent panel 
of three orthopedic practitioners not otherwise involved in the study. Clinical evidence 
will be evaluated as either union or nonunion.  
MSC concentration will be determined using FACS analysis of the concentrated 
bone marrow aspirate following standard cell sorting protocols. MSC populations will be 
identified as CD29+/CD105+/CD31- and their concentration will be calculated for both 
before and after concentration. 
Recruitment 
Patients with fracture nonunion who meet the inclusion and exclusion criteria will 
be recruited from the outpatient orthopedic clinics of Boston Medical Center, Brigham 
and Women’s Hospital, and Massachusetts General Hospital. Each institution will be 
responsible for generating a list of candidates who receive orthopedic care at their 
facility. Presentations will also be given at various conferences and meetings in order to 
make providers aware of this trial and to bolster recruitment. Candidates will be initially 
informed of this study by mail one week prior to their 9 month follow up appointment 
with their orthopedic provider. At the time of the visit, the investigators will meet with 
the patients to provide further details about the trial including risks and benefits. 
Individuals who choose to be enrolled will sign a consent form to be registered for the 
study.  
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Data collection 
Before treatment is initiated, a complete physical exam and medical history is required of 
each patient. Appropriate case-specific radiographic images of fractures are required. 
Each patient recall will involve standard radiographic evaluation based on the mRUST 
standardized scoring method. This scoring will be done by five independent readers and 
the ICC will examine the results to make sure the scores are unbiased. Review of the 
electronic medical record for each patient will catalogue demographic data as well as 
comorbidities such as diabetes, rheumatoid arthritis, and smoking status. 
Data analysis 
Demographic data such as gender, and ethnicity will be analyzed using 
descriptive statistics. Additional descriptive statistics will be used to characterize 
anatomic location of the fracture in the tibia as well as radiographic features such as 
comminution, displacement, and angulation. 
A Pearson’s chi squared test will be used to analyze the primary outcome: fracture 
union 9 months post-intervention.  This analysis will be carried out on the radiographic 
evidence, the clinical evidence, and the combined data. A modified RUST score of 11 
will be considered union based on the study performed by Litrentra et al.78  If any 
discrepancy exists between radiographic and clinical evidence of union, the outcome will 
be declared as nonunion for the combined analysis. Confounding variables such as 
smoking status and diabetes will be adjusted for using multiple logistic regression 
analysis. Furthermore, SF-12 results will be analyzed with respect to intervention using 
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student’s t-test analysis to investigate global health outcomes and surgical management.  
Confounding variables, as above, will be adjusted for using multiple linear regression. 
The association between fluorescence activated cell sorting (FACS) and mRUST 
scores will be statistically analyzed using the non-parametric Spearman’s rank-order 
correlation analysis.  
Timeline and resources 
 In the summer of 2018, the study proposal will be submitted to the IRB. Upon 
approval, several weeks of coordination between the orthopedic clinics at Boston Medical 
Center, Brigham and Women’s Hospital, and Massachusetts’s General Hospital will take 
place. Staff will be informed of the study and presentations will be made regarding the 
biological basis and previous clinical data supporting the treatment. Once recruitment 
begins, the study is expected to run between five and six years for recruitment, treatment, 
and follow-up. Data analysis and independent evaluation of the data is expected to take 
up to 1 year. The total projected timeframe of this study is six to seven years. 
 Resource requirements for this study include both diagnostic instruments and 
personnel at each clinical site.   A study coordinator will be responsible for the logistic 
oversight of the study. Radiographic imaging modalities such as X-ray, CT, and MRI will 
be necessary. Experienced surgical teams for both treatment arms will be necessary as 
well as experienced interventional radiologists for application of the MSCs. Five 
independent radiologists will be needed for evaluation of the radiological data. Three 
independent orthopedic practitioners not otherwise involved in the study will be required 
for evaluation of clinical outcomes. Access to the electronic medical record will be 
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necessary to retrieve the clinical and demographic data. Reagents and equipment required 
for preparation of cells for flow cytometry as well as access to a FACS core facility will 
be necessary for the evaluation of MSC concentration. A data manager responsible for 
blinding the radiologic and clinical data as well as a statistician to analyze the data will be 
needed for study completion. 
Institutional Review Board 
Prior to the initiation of this study, permission must be obtained from the IRB. 
The protocol of this study will be submitted for full IRB review to the Boston University 
Medical Campus IRB and to the corresponding IRBs of the participating institutions. Full 
IRB approval is necessary given the experimental nature of the intervention and the 
possibility for morbidity and mortality to any human subjects enrolled within this trial. 
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CONCLUSION 
Discussion 
The study detailed herein has inherent limitations. Fracture nonunion lacks a 
standardized set of replicable criteria, and thus is a determination based on clinical 
experience.  This study attempts to control for this by using blinded evaluators and 
assessing one single data point: the six-month follow-up. Also, the interventions can vary 
in technique from surgeon to surgeon. Detailed description of the interventions is 
intended to create a more uniform technique, but variations between surgeons is to be 
expected. Additionally, the patients recruited to this study will all be from the 
Northeastern United States, a population that has been shown to have lower overall levels 
of Vitamin D,80 an important factor in bone health. This may influence the 
generalizability of the results to the broader population.  
The proposed study is not a small one, and thus obstacles inherent in the scope of 
this study are anticipated. Coordination between multiple hospitals and access to 
electronic records may prove cumbersome. This study hopes to address these obstacles 
by using the services of a dedicated study coordinator. In addition, patients may be lost to 
follow up and never return for a 9-month evaluation, particularly if they have healed 
clinically. While the sample size is adjusted accordingly, follow-up loss may exceed 
anticipated rates. Explicit emphasis on the importance of re-evaluation should be 
imparted to each patient enrolled in this study. 
The strengths of this study are in its prospective and blinded design, as well as its 
correlation between clinical and radiographic outcomes with the concentration of MSCs 
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applied.  Additionally, the control group in this study will receive the gold standard of 
care for fracture nonunion, providing a compelling comparison for this novel therapeutic. 
Summary 
Fracture nonunion is a debilitating and costly condition. Nonunions may persist 
despite appropriate surgical and nonsurgical efforts leading to prolonged pain and 
disability. While autologous iliac crest bone graft remains the gold standard of therapy, 
this intervention is associated with significant morbidity to the donor site. Mesenchymal 
stem cells represent a promising osteogenic therapeutic intervention. Percutaneous 
injection of MSCs is a relatively non-invasive intervention and is associated with less 
morbidity than iliac crest bone graft harvest.  
Clinical and/or public health significance 
Patients who suffer from fracture nonunion face chronic pain daily, eroding their 
physical and mental health. By exploring a less invasive alternative to iliac crest bone 
grafts, this study aims to show that percutaneous application of MSCs can lead to better 
outcomes and reduced economic burden. This would effectively translate the biological 
properties of MSCs into evidence-based clinical practice. 
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